Ali L, Wesslén N, Hellman B
Department of Medical Cell Biology, Biomedicum, Uppsala, Sweden.
Eur J Pharmacol. 1988 Dec 13;158(3):257-62. doi: 10.1016/0014-2999(88)90075-1.
Sodium was measured in rat pancreatic islet exposed to tolbutamide, glipizide, diazoxide or sulfisomidine. When added to a medium with physiologically balanced cations these sulphonamides induced a significant rise of the islet content of sodium. The insulin-releasing compounds, tolbutamide and glipizide, had effects opposite to those of the hyperglycemic diazoxide in counteracting the increase of sodium obtained with removal of K+. The tolbutamide-induced increase in sodium was reversed to a decrease when Ca2+ was omitted from the incubation medium. The increase of sodium, which was also seen with non-hypoglycemic sulphonamides, is itself not sufficient for initiating insulin release. However, it may well represent an important mechanism contributing to the secretory response initiated by Ca2+ entry into the sulfonylurea-depolarized beta-cell.
在暴露于甲苯磺丁脲、格列吡嗪、二氮嗪或磺胺异嘧啶的大鼠胰岛中测量了钠含量。当将这些磺胺类药物添加到具有生理平衡阳离子的培养基中时,它们会导致胰岛钠含量显著升高。胰岛素释放化合物甲苯磺丁脲和格列吡嗪在抵消因去除钾离子而导致的钠增加方面,其作用与高血糖药物二氮嗪相反。当从孵育培养基中省略钙离子时,甲苯磺丁脲诱导的钠增加会逆转至减少。非降血糖磺胺类药物也会出现钠增加的情况,但其本身并不足以引发胰岛素释放。然而,它很可能代表了一种重要机制,有助于由钙离子进入磺酰脲去极化的β细胞引发的分泌反应。